KabaFusion selected by UCB to provide Rystiggo to gMG patients
Approved infusion therapy now available to US patients at home
The home infusion company KabaFusion has announced that UCB has tapped it as a limited U.S. distribution partner for Rystiggo (rozanolixizumab-noli), the first therapy approved for adults with the two most common subtypes of generalized myasthenia gravis (gMG).
Following its June approval by the U.S. Food and Drug Administration, the UCB therapy is now commercially available to eligible gMG patients with antibodies against either the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins.
Rystiggo is administered through subcutaneous or under-the-skin injections, which can be given to patients at home with the use of a specialty pharmacy. UCB announced in July that it was setting up a limited network of such pharmacies in the U.S. that were capable of administering the therapy in a home setting.
“KabaFusion is proud to be a leader in home infusion and providing access to patients with new drugs that will improve their quality of life,” Sohail Masood, KabaFusion’s founder and CEO, said in a company press release.
“We have a well-established history of successfully managing patients with myasthenia gravis and neuromuscular conditions and we are proud to have been selected by UCB as a limited distribution partner to provide Rystiggo to patients and providers,” Masood said.
KabaFusion home infusion company serves patients in 46 states
Based in California and Massachusetts and founded in 2010, KabaFusion is a national provider of chronic and acute infusion therapies. It serves patients in 46 states through its network of home infusion pharmacies, alternative infusion sites, and home health agencies.
Rystiggo, now also up for approval in Europe and Japan, is designed to reduce the levels of antibodies driving gMG, thereby lessening the muscle weakness and fatigue that characterize the disease, along with other symptoms.
The medication is meant to be delivered by a healthcare provider at doctors’ offices, hospital outpatient clinics, and independent infusion centers by injection every week for six weeks. Additional six-week cycles depend on the patient’s clinical response.
Patients using Rystiggo, as well as their caregivers, may enroll in ONWARD, UCB’s personalized patient support program for those being treated with its medicines for rare diseases.
All participants will have a medically trained care coordinator assigned to them throughout treatment who can answer questions regarding their insurance coverage and explain financial assistance options for access to Rystiggo, which is listed at a price of $6,050 per vial. The coordinators also can provide other resources and help with treatment tracking.
UCB is conducting a Phase 3 clinical trial (NCT05681715) to assess whether Rystiggo can be self-administered at home with appropriate training. Those results are expected next year. The study may still be recruiting adults with gMG at sites in the U.S. and Europe.
About the Author
